SOURCE: Paragon Financial Limited

Paragon Financial Limited

December 08, 2011 08:16 ET

Oncothyreon and Cyclacel Pharmaceuticals -- Strong Examples of Recession Proof Growth

The Paragon Report Provides Equity Research on Oncothyreon & Cyclacel Pharmaceuticals

NEW YORK, NY--(Marketwire - Dec 8, 2011) - The Biotechnology industry has long been regarded as a "Recession Proof" sector of the economy. Even during periods of financial turmoil, most people will continue purchasing their medication. Studies show the number of new drugs being developed is growing at a rapid clip, while the number of small biotech firms continues to increase. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Oncothyreon, Inc. (NASDAQ: ONTY) and Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC). Access to the full company reports can be found at:

While Big Pharma continues to shed jobs due to consolidation in the space, smaller biotech firms are showing signs of growth. According to a recent article from Genetic Engineering and Biotechnology News, the most recently available figures by Battelle show that US biotech employment inched up 0.2% during the period between 2007 and 2009, to about 1.36 million jobs. The number of bioscience establishments climbed between '08 and '09 from 47,593 to 48,059, the article finds.

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at and get exclusive access to our numerous stock reports and industry newsletters.

Oncothyreon Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic products for the treatment of cancer. Shares of the company have been on the upswing of late as ONTY's CEO Bob Kirkman is rumored to have return from an unexplained medical leave, Xconomy reports. Kirkman declined to comment, saying he still has to put out the usual regulatory disclosure about his return.

Cyclacel Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the discovery, development, and commercialization of mechanism-targeted drugs to treat human cancers and other serious disorders. The Company's net loss applicable to common shareholders for the third quarter of 2011 was $3.6 million, or $0.07 per share, compared to a net loss applicable to common shareholders of $4.0 million or $0.11 per share, for the third quarter of 2010.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at